Translational Relevance of Advanced Age and Atherosclerosis in Preclinical Trials of Biotherapies for Peripheral Artery Disease

Keith A. Webster

DOI: https://doi.org/10.3390/genes15010135

IF: 4.141

2024-01-23

Genes

Abstract:Approximately 6% of adults worldwide suffer from peripheral artery disease (PAD), primarily caused by atherosclerosis of lower limb arteries. Despite optimal medical care and revascularization, many PAD patients remain symptomatic and progress to critical limb ischemia (CLI) and risk major amputation. Delivery of pro-angiogenic factors as proteins or DNA, stem, or progenitor cells confers vascular regeneration and functional recovery in animal models of CLI, but the effects are not well replicated in patients and no pro-angiogenic biopharmacological procedures are approved in the US, EU, or China. The reasons are unclear, but animal models that do not represent clinical PAD/CLI are implicated. Consequently, it is unclear whether the obstacles to clinical success lie in the toxic biochemical milieu of human CLI, or in procedures that were optimized on inappropriate models. The question is significant because the former case requires abandonment of current strategies, while the latter encourages continued optimization. These issues are discussed in the context of relevant preclinical and clinical data, and it is concluded that preclinical mouse models that include age and atherosclerosis as the only comorbidities that are consistently present and active in clinical trial patients are necessary to predict clinical success. Of the reviewed materials, no biopharmacological procedure that failed in clinical trials had been tested in animal models that included advanced age and atherosclerosis relevant to PAD/CLI.

genetics & heredity

What problem does this paper attempt to address?

This paper focuses on the importance of aging and atherosclerosis, two comorbid factors, in clinical trials of biologic therapy for peripheral artery disease (PAD). The authors point out that although biologic therapies such as growth factors, stem cells, or gene therapy have been shown to promote vascular regeneration and functional recovery in animal models, their effects in patients are not ideal and there are currently no approved treatment options by the US, EU, or China. The paper discusses possible reasons for this, including inappropriate animal models that do not reflect the common comorbidities of aging and atherosclerosis seen in clinical patients. The authors emphasize the need for preclinical models that include aging and atherosclerosis consistent with PAD/CLI patients in order to predict the success of clinical trials. The paper also reviews early clinical trials, noting that while cell therapy has shown some safety and efficacy, overall effects are not significant and there are many challenges, such as a lack of appropriate models to mimic the toxic biochemical environment of human CLI. The paper concludes by proposing further research and optimization strategies to address the challenges of biologic therapy in clinical translation.